HITIQ Selected for Major Brain Injury Research Program

Open PDF
Stock HITIQ Ltd (HIQ.ASX)
Release Time 6 Nov 2025, 9:54 a.m.
Price Sensitive Yes
 HITIQ Selected for Major Brain Injury Research Program
Key Points
  • Major Research Partnership: Monash University secures ARC Discovery Project grant featuring HITIQ PROTEQTâ„¢ technology
  • Significant Commercial Pre-commitment: 400 PROTEQTâ„¢ units to be supplied in January 2026, generating $200,000 in revenue
  • Groundbreaking Research: Study combining biomechanics and biomarkers to establish brain injury thresholds
Full Summary

HITIQ Limited (ASX: HIQ) has announced that Monash University has been awarded a prestigious Australian Research Council (ARC) Discovery Project grant of $799,866 for groundbreaking brain injury research that will utilize HITIQ PROTEQTâ„¢ instrumented mouthguards as a core technology platform. The research program, titled 'Combining biomechanics and biomarkers to establish brain injury thresholds', aims to integrate real-time biomechanical head impact data from PROTEQTâ„¢ with advanced biomarker analysis to establish definitive thresholds for brain injury risk from cumulative impact exposure. Monash University has formally confirmed the selection of the HITIQ PROTEQTâ„¢ system as the preferred instrumented mouthguard platform for this project and provided a pre-commitment to purchase 400 units in January 2026 for $200,000. This partnership positions PROTEQTâ„¢ at the center of leading-edge concussion research that will inform international safety protocols and clinical guidelines, providing independent academic validation and establishing crucial clinical evidence for regulatory pathways and international adoption.

Guidance

The Monash University research program will generate $200,000 in revenue for HITIQ through the purchase of 400 PROTEQTâ„¢ units in January 2026.

Outlook

This ARC Discovery Project represents HITIQ's growing research partnership portfolio, which includes collaborations with leading universities and research institutions globally. These partnerships generate revenue while establishing the clinical evidence base necessary for regulatory approvals and adoption by major sporting organizations worldwide.